Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bahija Jallal: MedImmune's Modern Innovator

This article was originally published in Scrip

Executive Summary

When Dr Bahija Jallal stepped out of a conference room full of scientists she knew that her life had changed forever. She had just witnessed a patient personally thanking every person that had worked on a drug she had taken as part of a Phase I trial. Needless to say the trial, and the drug, had worked and the patient was overjoyed. "I remember vividly coming out of that room and thinking that was exactly what I want to do for the rest of my life," she recalls. "That was the beginning of a journey for me. I feel it’s a privilege to do this work."

You may also be interested in...



Jallal To Lead Immunocore, Building On Partnership She Forged At MedImmune

A key figure in AstraZeneca’s resurgence, Jallal now leaves to head up a clinical-stage firm. She’s been an outspoken advocate for greater gender equity in biopharma leadership.

Glass Ceiling Cracked; Pharma Forges Path To Gender Equality By 2040?

One woman CEO is an improvement, but at this rate gender equality won't arrive before immuno-oncology goes generic.

Welcome To Alexion 2.0

In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.

Topics

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel